Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70165 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Zubeyir Salis und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Montpellier and Physiology and Experimental Medicine of the Heart and Muscles, Montpellier, France. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Machine Learning. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration.
Methods
We analyzed 21,675 treatment courses for model training, 5,418 courses for internal validation, and 1,807 courses from Switzerland for external validation. Remission was defined as a Clinical Disease Activity Index score ≤2.8 within 6 to 24 months after treatment initiation or switching. An XGBoost model was trained on 63 baseline demographic and clinical variables. Model performance was evaluated using the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Predictor contributions were quantified using Shapley Additive Explanations values. A simplified model using the top 10 predictors and a logistic regression benchmark were also evaluated.
Results
In external validation, the full model achieved an AUC of 0.797 (95% confidence interval 0.774–0.821), sensitivity of 0.804, specificity of 0.650, PPV of 0.454, and NPV of 0.902. The simplified model performed comparably (AUC 0.802). Logistic regression using the same 10 predictors achieved an AUC of 0.809. Key predictors included patient global assessment, 28‐tender joint count, previous biologic/targeted synthetic disease‐modifying antirheumatic drug exposure, and Health Assessment Questionnaire Disability Index score.
Conclusion
Using routinely collected baseline data across 11 registries, prediction of remission showed limited discrimination and was best suited to ruling out remission. Performance was similar for a 10‐variable model and logistic regression, indicating limited incremental value of model complexity without richer predictors. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Montpellier and Physiology and Experimental Medicine of the Heart and Muscles, Montpellier, France.
- Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
- Geneva Center for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Centre Hospitalier de l'Université de Montréal, Institut de Recherche en Rhumatologie, Montréal, Québec, Canada.
- Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania.
- Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
ORCID-Profile: Zubeyir Salis, Florenzo Iannone, Tore K Kvien, Sella Provan, Michele Iudici
Zitieren
APA
Salis, Z., Mongin, D., Choquette, D., Coupal, L., Codreanu, C., Iannone, F., Caporali, R., Kvien, T. K., Provan, S., Fritsch-Stork, R., Nordström, D., Trokovic, N., Pavelka, K., Závada, J., Rodrigues, A., Rotar, Z., Sidiropoulos, P., Flouri, I., Lamacchia, C., …, & Finckh, A. (2026). Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration. Arthritis & Rheumatology. https://doi.org/10.1002/art.70165
Vancouver
Salis Z, Mongin D, Choquette D, Coupal L, Codreanu C, Iannone F, et al. Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration. Arthritis & Rheumatology. 2026. doi:10.1002/art.70165
BibTeX
@article{Salis2026,
author = {Salis, Zubeyir and Mongin, Denis and Choquette, Denis and Coupal, Louis and Codreanu, Catalin and Iannone, Florenzo and Caporali, Roberto and Kvien, Tore K and Provan, Sella and Fritsch-Stork, Ruth and Nordström, Dan and Trokovic, Nina and Pavelka, Karel and Závada, Jakub and Rodrigues, Ana and Rotar, Ziga and Sidiropoulos, Prodromos and Flouri, Irini and Lamacchia, Céline and Iudici, Michele and Courvoisier, Delphine and Lauper, Kim and Finckh, Axel},
title = {Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70165}
}
EUVIMED